The Consumer Advisor

The landscape of cancer treatment and the pharmaceutical industry is undergoing rapid transformation in 2025, driven by scientific breakthroughs, shifting drug sales rankings, and evolving strategies among top pharma companies. This article synthesizes the latest advances in cancer therapy, highlights the world’s top-selling drugs, and examines the leading pharmaceutical players shaping the future of oncology and global health. Latest Breakthroughs in Cancer Treatment (2025) The fight against cancer is being reshaped by a wave of innovations, many of which are already impacting clinical practice or are in advanced stages of development: 1. Next-Generation Immunotherapy Perhaps the most transformative breakthrough in modern oncology has been the rise of immunotherapy—a set of treatments that awaken the immune system to recognize and attack cancer cells. It is an idea as beautiful as it is powerful: train the body to see the enemy hiding in plain sight. Checkpoint inhibitors were the fir...

Gold and silver ETFs have shown strong performance in 2025, surpassing the S&P 500 amid inflation concerns, geopolitical tensions, and central bank buying.  This article updates the best-performing gold and silver ETFs based on recent data, including 1-year returns, assets under management (AUM), expense ratios, and key notes, evaluating their pros, cons, and attractiveness in the current market.The best gold and silver ETFs of 2025 are noted for exceptional performance, low expense ratios, and reliable tracking of precious metals’ prices. Returns have adjusted slightly since late August due to recent price movements, but momentum remains strong with gold and silver near record highs. Here are the top options across global and key regional markets as of September 2025: Best Gold ETFs of 2025 VanEck Gold Miners ETF (GDX) YTD Performance: +80–115% (reported range for September 2025) ( TradingView ) AUM: ~$16.5B (estimated, based on historical size and 2025 inflows)  Rationa...